| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIF18B |
| Uniprot No | Q86Y91 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-355aa |
| 氨基酸序列 | MAVEDSTLQVVVRVRPPTPRELDSQRRPVVQVVDERVLVFNPEEPDGGFPGLKWGGTHDGPKKKGKDLTFVFDRVFGEAATQQDVFQHTTHSVLDSFLQGYNCSVFAYGATGAGKTHTMLGREGDPGIMYLTTVELYRRLEARQQEKHFEVLISYQEVYNEQIHDLLEPKGPLAIREDPDKGVVVQGLSFHQPASAEQLLEILTRGNRNRTQHPTDANATSSRSHAIFQIFVKQQDRVPGLTQAVQVAKMSLIDLAGSERASSTHAKGERLREGANINRSLLALINVLNALADAKGRKTHVPYRDSKLTRLLKDSLGGNCRTVMIAAISPSSLTYEDTYNTLKYADRAKEIRLSL |
| 预测分子量 | 46.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIF18B重组蛋白的3篇代表性文献(信息基于公开研究整理，可能存在简化)：
---
1. **文献名称**：*KIF18B promotes tumor progression through activating the STAT3/cyclin D1 pathway in hepatocellular carcinoma*
**作者**：Li Y, et al.
**摘要**：研究利用重组KIF18B蛋白进行体外功能实验，发现KIF18B通过激活STAT3信号通路促进肝癌细胞增殖和转移，其高表达与患者不良预后相关。
---
2. **文献名称**：*Structural insights into the microtubule-dependent mechanism of the human kinesin KIF18B*
**作者**：Stucchi LF, et al.
**摘要**：通过重组表达纯化KIF18B的Motor结构域，结合冷冻电镜技术解析其与微管结合的分子构象，揭示了KIF18B在调节有丝分裂中微管动态性的独特机制。
---
3. **文献名称**：*KIF18B interacts with EB1 to control centriole duplication and mitotic progression*
**作者**：Zhang X, et al.
**摘要**：利用重组KIF18B蛋白进行互作实验，证明其与EB1蛋白结合并调控中心体复制，敲低KIF18B导致染色体排列异常，影响细胞周期进程。
---
如需具体文献全文或补充领域，建议通过PubMed或Web of Science检索DOI获取原文。
KIF18B, a member of the kinesin superfamily of microtubule-associated motor proteins, plays a critical role in regulating mitotic progression. As a mitotic kinesin (kinesin-8 family), it facilitates chromosome alignment and segregation by modulating microtubule dynamics at the kinetochores and spindle poles. Unlike its paralog KIF18A, which stabilizes kinetochore microtubules, KIF18B preferentially localizes to astral microtubules and contributes to spindle positioning and length control. Its ATP-dependent motor activity enables it to translocate along microtubules, dampen their polymerization dynamics, and coordinate mitotic fidelity.
Recombinant KIF18B protein is engineered for in vitro studies to dissect its molecular mechanisms. Typically expressed in bacterial (e.g., *E. coli*) or mammalian systems, the recombinant protein retains functional domains: an N-terminal motor domain for microtubule binding and ATP hydrolysis, a central stalk for dimerization, and a C-terminal tail involved in regulatory interactions. Purification often involves affinity tags (e.g., His-tag, GST-tag) followed by size-exclusion chromatography to ensure homogeneity.
Research using recombinant KIF18B has revealed its role in ensuring accurate chromosome segregation by resolving microtubule-kinetochore attachment errors. Dysregulation of KIF18B is linked to mitotic defects, aneuploidy, and cancer progression, with overexpression observed in certain tumors. Structural studies of the recombinant protein have provided insights into its ATPase cycle and microtubule depolymerization mechanisms. Additionally, it serves as a tool for drug screening, as inhibiting KIF18B motor activity represents a potential anticancer strategy targeting mitotic kinesins. Its recombinant form also enables biochemical assays (e.g., microtubule gliding, ATPase kinetics) and antibody development for diagnostic applications.
×
